Prof Humphrey Hodgson

Photo

Personal Profile

Name: Humphrey Hodgson Email: h.hodgson@ucl.ac.uk
Title: Prof Tel:
Department: Div of Medicine Fax:
Position: Honorary Emeritus Address: , , ,
Research Domain: Basic Life Sciences, Experimental Medicine, Infection, Immunology & Inflammation, Personalised Medicine Web Page:  

Profile

Research Description

Professor Humphrey Hodgson Sheila Sherlock Professor of Medicine Director of the Centre for Hepatology Vice-Dean and Campus Director Personal Details: Royal Free and University College Medical School ( University College London ) Hampstead Campus Centre for Hepatology, Department of Medicine Rowland Hill Street London NW3 2PF UK Phone: Fax: Email: +44 (0)20 7433 2850/1 +44 (0)20 7433 2852 h.hodgson@medsch.ucl.ac.uk Career Details: 1999-present: UCL Director of the Centre for Hepatology, Royal Free and University College Medical School Past appointments 1996-1999 Imperial College School of Medicine, London Professor of Medicine/Honorary Consultant Physician Hammersmith Hospital , London 1992-1995 Professor of Gastroenterology/Honorary Consultant Physician, Royal Postgraduate Medical School 1987-1991 Reader in Gastroenterology/Consultant Physician, Royal Postgraduate Medical School Hammersmith Hospital , London Qualifications B.A., Oxon, Animal Physiology (First Class) 1966, B.Sc., Oxon 1969 B.M., B.Ch., Oxon 1970, M.A., Oxon 1970, M.R.C.P., (UK) 1972 D.M., Oxon 1977, F.R.C.P. 1983 F Med Sci 2002 Research Interests: Exploiting liver cell biology for therapeutic ends. Current projects involve: * In vivo gene transfer to hepatocytes in animals, in particular using growth factors to induce hepatocyte DNA synthesis in intact liver to allow retroviral gene transfer * Use of growth factors to enhance size and function of intact liver in vitro, in particular investigating efficacy and mechanism of tri-iodothyronine as a primary mitogen * Identification of toxic factors in liver failure plasma * Development of liver cell culture techniques to provide biological component of a bio-artificial liver device * Investigation of pathophysiology of inflammatory disease affecting liver and gut.

Research Activities

Education Description

UCL Collaborators

External Collaborators

Publications

    2013

    • Ala A, Brown D, Khan K, Standish R, Odin JA, Fiel MI, Schiano TD, Hillan KJ, Rahman SA, Hodgson HJ, Dhillon AP (2013). Mucosal Addressin Cell Adhesion Molecule (MAdCAM-1) Expression Is Upregulated in the Cirrhotic Liver and Immunolocalises to the Peribiliary Plexus and Lymphoid Aggregates.. Dig Dis Sci, , - . doi:10.1007/s10620-013-2755-1

    2010

    • Hodgson HJF, Sherlock S (2010). Physical examination Coals to Newcastle?. BRIT MED J, 340, - . doi:10.1136/bmj.c287

    2009

    • Soeda J, Morgan M, Mckee C, Sigalo B, Selden C, Hodgson HJF, Roskams T, Diehl AM, Oben JA (2009). NICOTINE INDUCES STEREOTYPIC FIBROGENIC CHANGES IN HUMAN PRIMARY HEPATIC STELLATE CELLS, VIA PI-3 AND P38 MAP KINASES, TRANSIDUCED THROUGH NICOTINIC ACETYLCHOLINE RECEPTORS, UPREGULATED IN HUMAN FIBROTIC NON-ALCOHOLIC STEATOHEPATITIS.
    • Mavri-Damelin D, Wilden J, Mani AR, Selden C, Hodgson HJF, Damelin LH (2009). The Use of 3-Aminophthalimide as a Pro-Chemiluminescent Label in Chemiluminescence and Fluorescence-Based Cellular Assays. BIOCONJUGATE CHEM, 20(2), 266 - 273. doi:10.1021/bc800361r

    2008

    • Mavri-Damelin D, Damelin LH, Eaton S, Rees M, Selden C, Hodgson HJF (2008). Cells for bioartificial liver devices: The human hepatoma-derived cell line C3A produces urea but does not detoxify ammonia. BIOTECHNOL BIOENG, 99(3), 644 - 651. doi:10.1002/bit.21599

    2007

    • Selden C, Mellor N, Rees M, Laurson J, Kirwan M, Escors D, Collins M, Hodgson H (2007). Growth factors improve gene expression after lentiviral transduction in human adult and fetal hepatocytes. J Gene Med., 9(2), 67 - 76. doi:10.1002/jgm.1000
    • Mavri-Damelin D, Eaton S, Damelin LH, Rees M, Hodgson HJ, Selden C (2007). Ornithine transcarbamylase and arginase I deficiency are responsible for diminished urea cycle function in the human hepatoblastoma cell line HepG2. Int.J Biochem.Cell Biol., 39(3), 555 - 564. doi:10.1016/j.biocel.2006.10.007
    • Damelin LH, Coward S, Kirwan M, Collins P, Selden C, Hodgson HJ (2007). Fat-loaded HepG2 spheroids exhibit enhanced protection from Pro-oxidant and cytokine induced damage. J Cell Biochem., 101(3), 723 - 734.
    • Laurson J, Selden C, Clements M, Mavri-Damelin D, Coward S, Lowdell M, Hodgson HJF (2007). Putative human liver progenitor cells in explanted liver. CELLS TISSUES ORGANS, 186(3), 180 - 191. doi:10.1159/000106360

    2006

    • Habib MM, Hodgson HJF, Davidson BR (2006). The role of glycine in hepatic ischemia-reperfusion injury. CURR PHARM DESIGN, 12(23), 2953 - 2967.
    • Mavri-Damelin D, Eaton S, Coward S, Damelin L, Rees M, Selden C, Hodgson HJF (2006). Restoring urea cycle function in HepG2 cells by multiple gene transfer; A cell source for a bio-artificial liver device.

    2005

    • Malik R, Habib M, Tootle R, Hodgson H (2005). Exogenous thryoid hormone induces liver enlargement, whilst maintaining regenerative potential: a study relevant to donor preconditioning.. American Journal of Transplantation, 5(8), 1801 - 1807. doi:10.1111/j.1600-6143.2005.00949.x
    • Coward SM, Selden C, Mantalaris A, Hodgson HJ (2005). Proliferation rates of HepG2 cells encapsulated in alginate are increased in a microgravity environment compared with static cultures.. Artificial Organs, 29(2), 152 - 158.
    • Habib MM, Selden C, Hodgson HFJ, Davidson BR (2005). Regeneration of the ischaemic liver remnant and effect of glycine.
    • Hodgson H (2005). c-met—there when it's needed?. Journal of Hepatology, 43(3), 544 - 546.
    • Malik R, Bungay A, Riemann M, Schmid R, Brown D, Hubank M, Selden C, Hodgson H (2005). Stimulation of hepatocyte proliferation and liver growth by triodothyronine (T3) and it's relationship to Bcl-3 expression.
    • Rahman TM, Diakanov I, Selden C, Hodgson H (2005). Co-transplantation of encapsulated HepG2 and rat Sertoli cells improves outcome in a thioacetamide induced rat model of acute hepatic failure.. Transplant International, 18(8), 1001 - 1009. doi:10.1111/j.1432-2277.2005.00156.x
    • Habib MM, Selden C, Hodgson HFJ, Davidson BR (2005). Transient ischaemia and reperfusion impairs early regenerative response in the hepatic remnant.
    • Laurson J, Selden C, Hodgson HJ (2005). Hepatocyte progenitors in man and in rodents-multiple pathways, multiple candidates.. Int J Exp Pathol., 86(1), 1 - 18.
    • Saich R, Collins P, Ala A, Standish R, Hodgson H (2005). Benign recurrent intrahepatic cholestasis with secondary renal impairment treated with extracorporeal albumin dialysis.. European Journal of Gastroenterology and Hepatology, 17(5), 585 - 588.
    • Collins P, Jones C, Choudhury S, Damelin L, Hodgson H (2005). Increased expression of uncoupling protein 2 in HepG2 cells attenuates oxidative damage and apoptosis.. Liver International, 25(4), 880 - 7.

    2004

    • Craig CE, Quaglia A, Selden C, Lowdell M, Hodgson H, Dhillon A (2004). The histopathology of regeneration in massive hepatic necrosis. SEMINARS IN LIVER DISEASE, 24(1), 49 - 64.
    • Lindsay JO, Sandison A, Cohen P, Brennan FM, Hodgson HJ (2004). IL-10 gene therapy is therapeutic for dextran sodium sulfate-induced murine colitis.. Digestive Diseases and Sciences, 49(7), 1327 - 1334.
    • Damelin LH, Coward S, Choudhury SF, Chalmers SA, Cox IJ, Robertson NJ, Revial G, Miles M, Tootle R, Hodgson HJ, Selden C (2004). Altered mitochondrial function and cholesterol synthesis influences protein synthesis in extended HepG2 spheroid cultures.. Archives of Biochemistry and Biophysics, 432(2), 167 - 177.
    • Rahman TM, Selden C, Khalil M, Diakanov I, Hodgson HJ (2004). Alginate-encapsulated human hepatoblastoma cells in an extracorporeal perfusion system improve some systemic parameters of liver failure in a xenogeneic model.. Artificial Organs, 28(5), 476 - 482.
    • Selden C, Hodgson H (2004). Cellular therapies for liver replacement.. Transplant Immunology, 12(3), 273 - 288.
    • Mellor N, Themis M, Selden C, Jones M, Hodgson HJ (2004). Characteristics of murine histidinaemia and its potential for genetic manipulation.. Liver International, 24(4), 354 - 360.

    2003

    • Damelin LH, Cox IJ, Robertson NJ, Khalil M, Tootle R, Coward S, Choudhury S, Hodgson HJF, Selden C (2003). Modulated mitochondrial activity corresponds with a decline in liver-specific function in 3-D HepG2 culture.
    • Craig CEH, Quaglia A, Savage K, Lowdell MW, Seldon C, Sim R, North J, Prentice HG, Hodgson H, Dhillon AP (2003). Hepatocyte progenitor cells in massive hepatic necrosis.
    • Ala A, Dhillon AP, Hodgson HJ (2003). Role of cell adhesion molecules in leukocyte recruitment in the liver and gut. International Journal of Experimental Pathology, 84(1), 1 - 16.
    • Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ (2003). Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut, 52(7), 981 - 987.
    • Selden C, Casbard A, Themis M, Hodgson HJ (2003). Characterization of long-term survival of syngeneic hepatocytes in rat peritoneum. Cell Transplantation, 12(6), 569 - 578.
    • Rahman TM, Hodgson HJF (2003). The effects of early and late administration of inhibitors of inducible nitric oxide synthase in a thioacetamide-induced model of acute hepatic failure in the rat. Journal of Hepatology, 38(5), 583 - 590. doi:10.1016/S0168-8278(03)00050-3
    • Lindsay JO, Ciesielski CJ, Scheinin T, Brennan FM, Hodgson HJ (2003). Local delivery of adenoviral vectors encoding murine interleukin 10 induces colonic interleukin 10 production and is therapeutic for murine colitis. Gut, 52(3), 363 - 369. doi:10.1136/gut.52.3.363
    • Ala A, Brown D, Stubbs M, Jacobs R, Hodgson H (2003). Mucosal cell adhesion molecule (MAdCAM-1) expression in chronic liver disease and development of an in vitro model to investigate therapeutic modulation.
    • Craig CEH, Quaglia A, Savage K, Lowdell MW, Selden C, Sim R, North J, Prentice HG, Hodgson H, Dhillon AP (2003). Hepatocyte progenitor cells in massive hepatic necrosis.
    • Malik R, Mellor N, Selden C, Hodgson H (2003). Triiodothyronine enhances the regenerative capacity of the liver following partial hepatectomy. Hepatology, 37(1), 79 - 86. doi:10.1053/jhep.2003.50001
    • Malik R, Khan K, Rahma T, Hodgson H (2003). Mitogenic therapy administered after the induction of liver failure enhances the proliferative response of hepatocytes within the failing organ.
    • Selden C, Coward S, Jones C, Khalil M, Mavri D, Hodgson HJF (2003). Designer cells for a bioartificial liver - Restoring ornithine carbamyl transferase (OTC) activity to Hep G2 cells by transfection and 3-dimensional culture restores urea synthesis to in vivo levels..
    • Selden AC, Chalmers SA, Jones C, Standish R, Quaglia A, Rolando N, Burroughs AK, Rolles K, Dhillon AP, Hodgson HJF (2003). Epithelial colonies cultured from human explanted liver in subacute hepatic failure exhibit hepatocyte, biliary epithelial, and stem cell phenotypic markers. Stem Cells, 21(6), 624 - 631. doi:10.1634/stemcells.21-6-624
    • Alsowmely A, Grasso A, Hodgson H, Burroughs A, Davidson B, Quaglia A, Dhillon A, Rolles K (2003). Life-table analysis of survival after liver transplantation for hepatocellular carcinoma: A single centre study.
    • Hodgson H (2003). Liver cells: biology to therapeutics. Clinical Medicine, 3(2), 161 - 165.

    2002

    • Malik R, Selden C, Hodgson H (2002). The role of non-parenchymal cells in liver growth. Seminars in Cell and Developmental Biology, 13(6), 425 - 431.
    • Ala A, Standish R, Khan K, Hillan K, Dhillon A, Hodgson H (2002). Podoplanin and mucosal addressin cell adhesion molecule-1 (MAdCAM-1) localisation in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). Journal of Hepatology, 36, 501 - .
    • Selden C, Hodgson HJF (2002). Engineering the liver. In Polak JM, Hench L, Kemp P (Ed.), Future strategies for tissue and organ replacement (pp. 141 - 182). : Imperial College Press.
    • Hodgson HJF (2002). Carcinoid tumours and the carcinoid syndrome. In Wass JAH, Shalet SM (Ed.), Oxford Textbook of Endocrinology and Diabetes (pp. 871 - 876). : .
    • McCloskey P, Tootle R, Selden C, Larsen F, Roberts E, Hodgson HJ (2002). Modulation of hepatocyte function in an immortalized human hepatocyte cell line following exposure to liver-failure plasma. Artificial Organs, 26(4), 340 - 348.
    • Hodgson H (2002). Sheila Sherlock's legacy. The Lancet, 359(9305), 460 - .
    • Ala A, Standish R, Khan K, Stubbs M, Hillan K, Dhillon AP, Hodgson HJF (2002). Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and podoplanin localisation in primary sclerosing cholangitis (PSC) & primary biliary cirrhosis (PBC). Gut, 50, 202 - .
    • Hodgson H (2002). Hormonal therapy for gastrointestinal angiodysplasia. The Lancet, 359(9318), 1630 - 1631.
    • Lindsay J, Van Montfrans C, Brennan F, Van Deventer S, Drillenburg P, Hodgson H, Te VA, Sol Rodriguez PM (2002). IL-10 gene therapy prevents TNBS-induced colitis. Gene Therapy, 9(24), 1715 - 1721.
    • Hodgson H, Rahman TM, Selden C (2002). Co-transplantation of hepatocytes and non-parenchymal cells. Hepatocyte Transplantation. In Gupta S, Jansen P, Klempnauer J, Manns M (Ed.), (pp. 51 - 59). : Kluwer Ac Publishers.
    • Malik R, Hodgson H (2002). The relationship between the thyroid gland and the liver. QJM, 95(9), 559 - 569.
    • Ala A, Standish R, Khan K, Stubbs M, Hillan K, Dhillon AP, Hodgson HJF (2002). Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) and podoplanin localisation in primary sclerosing cholangitis (PSC) & primary biliary cirrhosis (PBC). GUT, 50, A56 - A56.
    • Alsowmely AM, Hodgson HJ (2002). Non-surgical treatment of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 16(1), 1 - 15.
    • Rahman TM, Selden AC, Hodgson HJ (2002). A novel model of acetaminophen-induced acute hepatic failure in rabbits. Journal Of Surgical Research, 106(2), 264 - 272.
    • Hodgson HJF (2002). Biomarkers in gastrointestinal disease. In Trull A, Demers L, Holt D, Johnston A, Tredger JM (Ed.), Biomarkers of Disease: An Evidence-Based Approach (pp. 265 - 271). : Cambridge University Press.
    • Alsowmely AM, Hodgson HJF (2002). Review article: non-surgical treatment of hepatocellular carcinoma. Alimentary Pharmacology and Therapeutics, 16(1), 1 - 15.

    2001

    • Khalil M, Shariat-Panahi A, Tootle R, Ryder T, McCloskey P, Roberts E, Hodgson H, Selden C (2001). Human hepatocyte cell lines proliferating as cohesive spheroid colonies in alginate markedly upregulate both synthetic and detoxificatory liver function. Journal of Hepatology, 34(1), 68 - 77. doi:10.1016/S0168-8278(00)00080-5
    • (2001). Immortalization of human hepatocytes by temperature-sensitive SV40 large-T antigen. In Vitro Cellular and Developmental Biology - Animal, 37(3), 166 - 168.
    • Gordon FH, Watkinson A, Hodgson H (2001). Vascular malformations of the gastrointestinal tract. Best Practice and Research Clinical Gastroenterology, 15(1), 41 - 58.
    • Ala A, Standish R, Khan K, Prasad N, Hillan K, Dhillon AP, Hodgson H (2001). Immmunohistochemical study of mucosal addressin cell adhesion molecule-1 (MAdCAM-1) expression in primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC). Hepatology, 34(4), 1404 - .
    • Elsheikh M, Hodgson HJ, Wass JA, Conway GS (2001). Hormone replacement therapy may improve hepatic function in women with Turner's syndrome. Clinical Endocrinology, 55(2), 227 - 231.
    • Rahman T, Hodgson H (2001). Clinical management of acute hepatic failure. Intensive Care Medicine, 27(3), 467 - 476.
    • Lindsay JO, Ciesielski CJ, Scheinin T, Hodgson HJ, Brennan FM (2001). The prevention and treatment of murine colitis using gene therapy with adenoviral vectors encoding IL-10. The Journal of Immunology, 166(12), 7625 - 7633.
    • Lindsay JO, Hodgson HJ (2001). Review article: the immunoregulatory cytokine interleukin-10--a therapy for Crohn's disease?. Alimentary Pharmacology and Therapeutics, 15(11), 1709 - 1716.

    2000

    • Hodgson HJF (2000). Whipple's disease. (Trophyrema Whippelii Infection). In Ledingham JGG, Warrell DA (Ed.), Concise Oxford Textbook of Medicine (pp. 554 - 555). : Oxford University Press.
    • Forbes SJ, Themis M, Alison MR, Shiota A, Kobayashi T, Coutelle C, Hodgson HJF (2000). Tri-iodothyronine and a deleted form of hepatocyte growth factor act synergistically to enhance liver proliferation and enable in vivo retroviral gene transfer via the peripheral venous system. Gene Therapy, 7(9), 784 - 789.
    • Forbes SJ, Themis M, Alison MR, Sarosi I, Coutelle C, Hodgson HJF (2000). Synergistic growth factors enhance rat liver proliferation and enable retroviral gene transfer via a peripheral vein. Gastroenterology, 118(3), 591 - 598.
    • Rahman TM, Hodgson HJF (2000). Artificial liver support - [double prime] Bridge to transplantation? [double prime]. Clinical Intensive Care, 11(5), 227 - 237.
    • Rahman TM, Hodgson HJF (2000). L-NAME and aminoguanidine (AMG): Selectivity and temporal differences in iNOS inhibition in a rat model of acute hepatic failure (AHF). Hepatology, 32(4 Pt 2), 395A - .
    • Rahman TM, Hodgson HJ (2000). Animal models of acute hepatic failure. International Journal of Experimental Pathology, 81(2), 145 - 157.
    • Selden C, Khalil M, Hodgson HJF (2000). Three dimensional culture upregulates extracellular matrix protein expression in human liver cell lines: A step towards mimicking the liver in vivo?. International Journal of Artificial Organs, 23(8), 535 - .
    • McCloskey PG, Selden C, Roberts E, Hodgson HJF (2000). Inhibition of tert-butylhydroperoxide (t-BH) induced oxidative stress in three human hepatocyte cell lines by pretreatment with 1,2:5,6- Dibenzylanthracence (DBA).
    • Mellor N, Themis M, Selden C, Jones M, Hodgson HJ (2000). Amelioration of murine histidinaemia using retroviral gene transfer.
    • Khalil M, Hodgson HJF, Ryder T, Selden C (2000). Enhancement of proliferation and function in 3-D spheroids of human hepatocyte cell lines by human extracellular matrix, but not chemical differentiating agents.
    • Hodgson HJF (2000). Azathioprine: effectiveness, action and use. In Modigliani R (Ed.), Inflammatory Bowel Disease (pp. 46 - ). : John Libbey Eurotext.
    • McCloskey PG, Tootle RA, Larsen S, Selden C, Roberts E, Hodgson HJF (2000). Modulation of hepatocyte function in a hepatocyte cell line following exposure to liver failure plasma.
    • Hodgson HJF (2000). Short Gut Syndrome. In Ledingham JGG, Warrell DA (Ed.), Concise Oxford Textbook of Medicine (pp. 555 - 556). : Oxford University Press.
    • Selden C, Khalil M, Hodgson H (2000). Three dimensional culture upregulates extracellular matrix protein expression in human liver cell lines--a step towards mimicking the liver in vivo?. International Journal of Artificial Organs, 23(11), 774 - 781.
    • Rahman TM, Hodgson HJF (2000). Low dose pentoxifylline (PTX) reduces mortality in a thioacetamide induced rat model of acute hepatic failure (AHF). Hepatology, 32(4 Pt 2), 395A - .

    1996

    • Smalley MJ, McCloskey P, Leiper K, OHare MJ, Hodgson HJF (1996). Cell strains derived from normal human hepatocytes by infection with a retrovirus containing the SV40 large-T-antigen.. HEPATOLOGY, 24(4), 539 - 539.